结果
发表于 2025-3-23 13:19:53
C. Cornadó,S. Vima-Grau,P. Garcia-Almirall, other regimens should not be withheld from women who cannot receive an anthracyline. Current clinical data also suggest a possible sensitivity to taxane-based therapy, especially when combined with an anthracycline. Trastuzumab-based therapy should be considered as first line therapy for women wit
主动
发表于 2025-3-23 14:36:23
autografts or the puzzling jaw osteonecrosis induced by antiresorptive agents that are otherwise effective in treating long-bone osteoporosis or metastatic resorptive lesions. Identifying bone site-specific biomarkers is therefore essential, firstly to determine why or how bone cell phenotypes vary
Synthesize
发表于 2025-3-23 21:29:33
http://reply.papertrans.cn/44/4306/430562/430562_13.png
包庇
发表于 2025-3-23 22:20:51
A. C. Azevedo,J. M. P. Q. Delgado,A. S. Guimarães,I. Ribeiro,R. Sousanow be assessed in cancer patients using immunocytochemical and molecular assays able to detect even single metastatic cells. However, careful validation of technically confounding variables, including choice of detection antibody, preparation of cellular samples, and size of analyzed sample volumes
一再烦扰
发表于 2025-3-24 06:21:53
http://reply.papertrans.cn/44/4306/430562/430562_15.png
seduce
发表于 2025-3-24 09:34:43
E. Possan,J. J. O. Andrade,D. C. C. Dal Molin,José Luis Duarte Ribeiro, specifically directed to the extracellular domain (ECD) of the HER2/neu oncoprotein. The HER2/neu ECD is shed from cancer cells into the circulation and is measurable by immunoassay. We performed an in-depth review of the peer-reviewed literature on circulating ECD levels with respect to prevalenc
忘恩负义的人
发表于 2025-3-24 13:36:23
E. F. Felix,E. Possan,R. Carrazedotic marker studies for breast cancer is inconsistent, and few such markers have been adopted for widespread use in clinical practice. This is problematic, as many patients are over-treated and many others are treated ineffectively. The deficiencies in clinical development of biomarkers may become mo
Aggregate
发表于 2025-3-24 18:45:06
C. Cornadó,S. Vima-Grau,P. Garcia-Almirall to date suggest that the proto-oncogene may be a predictive factor of response to several therapies that are commonly used to treat breast cancer. Tumors that are both hormone receptors and c-.-B2 positive may be associated with a relative resistance to tamoxifen. Preliminary data suggest that arom
Granular
发表于 2025-3-24 20:41:03
http://reply.papertrans.cn/44/4306/430562/430562_19.png
规章
发表于 2025-3-24 23:26:31
http://reply.papertrans.cn/44/4306/430562/430562_20.png